Delivering Drugs By Inhalation Becoming Attractive For Central Nervous System Therapeutics

Main Category: Pharma Industry / Biotech Industry
Article Date: 05 Feb 2008 - 13:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The challenges of delivering drugs to the central nervous system are well-documented. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.

These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

These findings are examined in a new and comprehensive survey written and researched by Greystone Associates. The report includes detailed analysis of approved and development-stage products, market sector participants and technology and formulation factors.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Greystone Associates